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Ellipticine is a natural plant product that has been found to be a powerful
anticancer drug. Although still unclear, its mechanism of action is considered to
be mainly based on DNA intercalation and/or the inhibition of topoisomerase
II. Many experimental data suggest an intercalation based on stacking
interactions along the major base-pair axis, but alternative binding modes have
been proposed, in particular for ellipticine derivatives. The 1.5 A˚ resolution
structure of ellipticine complexed to a 6 bp oligonucleotide unveils its mode of
binding and enables a detailed analysis of the distorting effects of the drug on
the DNA.
1. Introduction
Ellipticine (5,11-dimethyl-6H-pyrido[4,3-b]carbazole; Fig. 1) is a
natural plant alkaloid originally isolated from Ochrosia elliptica of
the Apocynaceae family that has been found to be a potent anti-
tumour agent (for a review, see Garbett & Graves, 2004). Many of its
more soluble derivatives, which have different DNA-binding affi-
nities, show antitumour and cytotoxic effects and exhibit promising
results in the treatment of breast-cancer metastases, kidney sarcomas,
brain tumours and myeloblastic leukaemia (Stiborova´ et al., 2001).
Although a multimodal mechanism of action on DNA is accepted
(Auclair, 1987), the effects of ellipticine derivatives are considered to
mainly be based on DNA intercalation and/or the inhibition of
topoisomerase II. Unfortunately, the exact mechanism remains
unclear as a faithful binding mode has not been fully depicted to date.
An early X-ray crystallographic structure of ellipticine complexed
with a self-complementary ribodinucleoside monophosphate (Jain et
al., 1979; NDB code DRBB11) shows that the drug binds as a parallel
base-stacking intercalator, similar to cryptolepine (Lisgarten et al.,
2002), actinomycin (Shinomiya et al., 1995) and acridine-type drugs
(Adams et al., 1999), which intercalate parallel to the base-pair
hydrogen bonds and stack its aromatic rings into the DNA bases. This
type of binding would be in keeping with the hydrodynamic studies
that assigned to ellipticine an unwinding angle equivalent to that of
the parallel base-stacking intercalator ethidium bromide (Kohn et al.,
1975), accepted as being approximately 26 (Wang, 1974). However,
because of the short length of the oligonucleotide used by Jain and
coworkers, it has been questioned whether that structure represents
the real DNA-binding mode (Garbett & Graves, 2004). Also,
molecular-dynamics simulations suggested an alternative binding
mode for one of its most studied derivatives, 9-hydroxyellipticine
(Elcock et al., 1996). According to these, 9-hydroxyellipticine would
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Figure 1
Chemical structure of ellipticine and the 9-hydroxyellipticine derivative.
intercalate in an orientation perpendicular to the long base-pair axis.
As every derivative may have a different binding mode, extensive and
accurate information on how the drugs of this family interact with
DNA is needed in order to understand their mechanism of action.
Here, we report the crystal structure determination of ellipticine in
complex with a 6 bp DNA at 1.5 A˚ resolution, compare it with the
previous crystallographic study of the same drug within a 2 bp
structure and discuss the effect of ellipticine intercalation on DNA
unwinding and lengthening.
2. Materials and methods
2.1. Crystallization and data collection
Crystallization conditions were screened using the Nucleic Acid
Mini Screen (Berger et al., 1996). Yellow hexagonal crystals were
grown at 293 K by the hanging-drop vapour-diffusion technique by
mixing 2.0 ml 5 mM ellipticine, 1.0 ml 1.5 mM d(CGATCG)2 and 1.0 ml
crystallization solution (12%MPD, 40 mM sodium cacodylate pH 5.5,
20 mM cobalt hexammine, 12 mM sodium chloride and 80 mM
potassium chloride) equilibrated against 500 ml 78% MPD. Both low-
and high-resolution data sets were collected on a 130 mmMAR CCD
detector (MAR Research) from a single crystal kept at 120 K using
synchrotron radiation ( = 0.976 A˚) at the ESRF (Grenoble)
microfocus beamline ID13. Data were indexed, integrated and scaled
with theXDS package (Kabsch, 1993), yielding an Rmerge of 8.7% and
a completeness of 99.6% in the resolution range 16.7–1.5 A˚. Data-
collection statistics are shown in Table 1.
2.2. Structure solution and refinement
The structure was solved by molecular replacement with AMoRe
(Navaza, 1994) using the DNA coordinates of the d(CGTACG)–
D232 structure (Shui et al., 2000; NDB code DD0018) as a starting
model. Reflections within the resolution range 16.7–3.0 A˚ were used
for rotation- and translation-function calculations. One clear solution
was found with a correlation coefficient of 54.8% and a crystallo-
graphic R factor of 46.8% (values for the second highest peak are 46.0
and 49.6%, respectively). Refinement followed with REFMAC5
(Murshudov et al., 1999). The optimum orientation of the intercalated
ellipticine was identified by placing the drug in each of the four
possible positions and refining until the best fit and corresponding
best R factor and Rfree were found. At this stage, an iterative
refinement procedure was carried out using REFMAC5 with ARP/
wARP (Perrakis et al., 1999), interspersed with inspection of electron-
density maps, water positioning and manual model rebuilding with
TURBO-FRODO (Roussel & Cambillau, 1989). All data were used
(16.7–1.5 A˚) with no low-resolution or  cutoff. A randomly selected
221 reflections (5%) were set aside for Rfree calculations. The final
refinement statistics are shown in Table 1. The helical parameters of
the DNA were analyzed with the program CURVES (Lavery &
Sklenar, 1988).
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Figure 2
Stereoviews of the ellipticine–DNA complex. (a) The bis-intercalated
d(CGATCG)2 hexanucleotide forming an asymmetric unit. The drug and each
strand of the DNA are represented in different colours. Red spheres represent Co
atoms. (b) 2Fo  Fc electron-density map at the area of the intercalated ligand,
looking into the minor groove. The map was contoured at the 1.0 level. (c)
Projection down the helix axis of a d(CpG)-d(GpC) dinucleotide with the
sandwiched ligand. (d) Superimposition of the structure from Jain et al. (1979) in
yellow and the equivalent part of the present structure in blue. (e) Three
asymmetric units illustrating the crystal packing of the ellipticine–d(CGATCG)2
structure. The drug is always coloured green and symmetry neighbours are in a
different colour. Water molecules (spheres) are included.
3. Results and discussion
The ellipticine–d(CGATCG)2 complex crystallizes in the hexagonal
space group P65, with unit-cell parameters a = 24.86, b = 24.86,
c = 78.86 A˚. The asymmetric unit consists of a DNA duplex plus two
drug molecules. The self-complementary hexamer adopts the double-
helical B-DNA conformation with an ellipticine molecule inter-
calated between the CpG steps at both ends of the duplex (Fig. 2a).
All atoms for both DNA and drug molecules have been modelled in
and are well defined, as indicated by the quality of the electron-
density maps (Fig. 2b). Inspection of 2Fo  Fc density maps
contoured at the 4.0 level revealed three putative hexammine cobalt
molecules. The exact location of their amine moieties could not be
determined and only the metal atom was added to the final model.
As might be expected owing to its shape and planar structure,
ellipticine intercalates by stacking interactions with DNA base pairs
(Fig. 2c). By these stacking interactions, ellipticine is aligned with its
major axis parallel to the Watson–Crick hydrogen bonds of the base
pairs. Despite sharing a common shape with cryptolepine, the
different distribution of N atoms and methyl residues in ellipticine
leads to a slightly different intercalation (Lisgarten et al., 2002).
Nitrogen N2 of both drug molecules faces the major groove of the
DNA. None of the drug molecules are hydrogen-bonded to the DNA.
Whereas one ellipticine molecule (E1) is kept in the intercalation site
solely by stacking interactions, nitrogen N2 of the other molecule
(E2) participates in a hydrogen bond with a water molecule (15W).
The structure confirms that ellipticine has a strong preference for the
d(GpC)-d(CpG) site, as no drug molecules are sandwiched in the
d(ApT)-d(TpA) site. The three hydrogen bonds between G and C
bases guarantee a tighter and thus more favourable site for inter-
calating a planar structure such as ellipticine.
In essence, the intercalation mode is similar to that described by
Jain et al. (1979) in the structure of the complex of ellipticine with a
self-complementary ribodinucleoside monophosphate. When super-
imposing the X-ray structures (Fig. 2d), the r.m.s. deviation for the
positions of common C10 atoms is 0.87 A˚. They have similar sugar–
phosphate backbone geometry, with a mixed sugar-puckering pattern
C30-endo/C20-endo at the immediate site of drug intercalation. There
is only a minor deviation of the ellipticine molecule position.
The ellipticine–d(CGATCG)2 complex is tightly packed in the
crystal, allowing only a 23% solvent content (27 water molecules in
the final asymmetric unit). A peculiar end-to-side interaction
between asymmetric units is the basis of the crystal packing. The C1–
G6 base pair of one end of the complex invades the major groove of a
neighbouring complex at the A3pT4 step and is held there by a direct
hydrogen bond between the N1 of guanine G6 and O40 of adenine A3
and two water-mediated hydrogen bonds (O6 of guanine G6 and O1
of phosphate from thymine T4, through water 18 W; O30 of cytosine
C5 and O1 of phosphate from guanine 6A, through water 3W). This
pattern of interactions is repeated in a reciprocal way, so that every
complex is both invaded and an invader at each end, as shown in
Fig. 2(e). Water molecules mediate the other packing interactions
between complexes.
As a result of the intercalation, the DNA is unwound and
lengthened (Fig. 3). The DNA in the complex has a B-like confor-
mation with Watson–Crick base pairing. However, in accommodating
the intercalated ellipticine molecule, the DNA assumes conforma-
tional parameters that are significantly different from average
B-DNAvalues. The DNA helical twist at the C1ApG2A-G6BpC5B and
C5ApG6A-G2BpC1B intercalation sites is 21.4 and 21.9
, respectively.
This is an unwinding angle of approximately 14 with respect to
standard B-DNA at the intercalation steps. The adjacent CpT steps
show an almost canonical B-DNA conformation (overwinding: 3.2
and 0.6), whereas the central ApT step is slightly unwound (6.8). At
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Figure 3
(a) Unwinding angle and (b) lengthening of the DNA in our crystals after
ellipticine (green diamond) intercalation, according to the analysis made with the
program CURVES (Lavery & Sklenar, 1988). Black lines indicate the expected
inter-base-pair rotation angles and distances for an average drug-free B-DNAwith
the same sequence generated with TURBO-FRODO (Roussel & Cambillau, 1989).
Coloured blocks with white values depict the actual winding and length between
contiguous base-pairs in our structure. Overall differences are given in black.
Table 1
Data- and structure-quality statistics for the ellipticine–d(CGATCG)2 complex at
1.5 A˚ resolution.
Values in parentheses are for the outer resolution shell (1.50–1.54 A˚).
Data quality
Resolution (A˚) 16.7–1.5
Rmerge (%) 8.7 (32.8)
Mean I/(I) 9.3 (4.6)
Completeness (%) 99.6 (99.7)
Multiplicity 5.2 (4.5)
Refinement
Data/parameter ratio 3.6
No. nucleic acid atoms 240
No. drug atoms 38
No. metal atoms 3 (Co)
No. solvent waters 27
Resolution used in refinement (A˚) 16.7–1.5
Rcryst 0.22 (0.24)
Rfree 0.24 (0.35)
R.m.s. deviation, bonds (A˚) 0.012
R.m.s. deviation, angles () 2.505
B values (A˚2)
C1A–G6B 31.40–27.48
E2 27.59
G2A–C5B 30.02–32.67
A3A–T4B 27.03–28.58
T4A–A3B 27.99–26.77
C5A–G2B 32.10–30.39
E1 29.22
G6A–C1B 30.12–31.48
Average B value 30.95
both intercalation sites, the bases are separated by 6.9 A˚. To achieve
this major opening of the bases, the sugar–phospate backbone is
distorted as discussed earlier.
Although the structure of ellipticine in complex with DNA strongly
suggests a similar binding for its derivatives, other binding modes for
the members of the ellipticine family cannot be ruled out. They may
be as diverse as their cytotoxic or anticancer effects. Further struc-
tural studies should confirm if the binding mode described here also
applies for the whole drug family.
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